Standard Protocol: Testing ASO Candidates in Cell Culture
A generic protocol compiled from 10 published studies that designed and tested antisense oligonucleotides in patient-derived cells.
Cell Preparation
Plate patient-derived fibroblasts (or disease-relevant cells: myoblasts for neuromuscular diseases, iPSC-derived neurons for CNS targets) in DMEM + 10–15% FBS + 1% antibiotics (penicillin/streptomycin) at 37°C, 5% CO₂.
Grow to 80–90% confluency in 24-well plates before treatment.
For muscle diseases: differentiate myoblasts in low-serum medium (2% horse serum + insulin-transferrin-selenite) for 3–7 days before treatment.
ASO Delivery
2'-MOE PS or 2'-OMe PS ASOs
Lipofectamine 3000
1.5 µL Lipofectamine 3000 + 2 µL P3000 reagent + 50 µL Opti-MEM per well (24-well plate). Alternatively: electroporation (Neon system: 2 pulses, 1400 V, 20 ms pulse width).
PMO ASOs
Endo-Porter
6 µM Endo-Porter in culture medium. Pre-heat ASO at 65°C for 10 min before dilution. PMOs require higher concentrations than PS-modified ASOs due to their uncharged backbone.
Gymnotic (free uptake)
No transfection reagent
Add PS-backbone ASOs directly to medium at higher concentrations (0.2–5 µM). Better models in vivo pharmacology but not all cell types support efficient uptake. Works best with 2'-MOE PS and LNA gapmers.
Concentration Ranges
| Chemistry | Delivery | Screening | Dose-response range |
|---|---|---|---|
| 2’-MOE PS (exon-inclusion) | Lipofection | 100–200 nM | 1–400 nM |
| 2’-MOE PS (gapmer) | Lipofection | 50 nM | 3–120 nM |
| 2’-MOE PS | Gymnotic | 1–2 µM | 0.2–5 µM |
| 2’-OMe PS | Lipofection | 200 nM | 50–400 nM |
| PMO | Endo-Porter | 5–10 µM | 1–10 µM |
Higher is not always better. 50 nM outperformed 200 nM for SMN2 splice correction (Wijaya et al., 2022), and concentrations above 1 µM caused toxicity and aberrant splicing (Kim et al., Nature 2023). Always include a toxicity ceiling in dose-response experiments.
Treatment Duration
| Readout | Duration post-treatment |
|---|---|
| RNA (splice correction / knockdown) | 24–48 hours |
| Protein (Western blot / immunofluorescence) | 48–72 hours |
| Gymnotic delivery | 3–7 days continuous exposure |
| Extended protein detection (e.g. dystrophin) | Detectable at 16 hours, stable for ≥1 week |
RNA Extraction and Target Measurement
Extraction
Lyse cells with TRIzol or column-based kit (PureLink RNA Mini Kit). DNase I treat. Quantify by NanoDrop or Qubit. Store at −80°C or proceed immediately to reverse transcription.
cDNA Synthesis
SuperScript IV VILO Master Mix or equivalent. Input: 100 ng–1 µg total RNA. Reverse transcription at 50–55°C for 10–30 min.
Splice-switching ASOs
RT-PCR (25–35 cycles), resolve on 2% agarose gel with SYBR Safe or Midori Green staining. Quantify band ratio (corrected / uncorrected transcript) by ImageJ densitometry. Validate band identity by Sanger sequencing. For higher quantitative accuracy, use digital droplet PCR (ddPCR).
Gapmer ASOs (RNase H)
qRT-PCR measuring target mRNA knockdown. Normalize to housekeeping gene (GAPDH or 18S rRNA). Report as % remaining mRNA relative to untreated control.
Protein Confirmation (recommended)
Western blot at 48–72 hours post-treatment. Normalize to loading control (GAPDH, α-tubulin). Compare to healthy control cell lysate using a calibration curve (healthy lysate serially diluted with untreated disease lysate). RNA-level correction does not always translate to protein restoration.
Controls
| Control | Purpose |
|---|---|
| Untreated cells | Baseline expression |
| Non-targeting ASO (same chemistry) | Sequence specificity — confirms effect is sequence-dependent, not chemistry-dependent |
| Mock transfection (reagent only) | Transfection reagent toxicity |
| Healthy or carrier cells | Normal expression reference — defines the therapeutic target level |
| Housekeeping gene (GAPDH, 18S) | RNA loading normalization |
Dose-Response Curve
- Test 6–10 concentrations spanning 2–3 orders of magnitude.
- Minimum 3 independent biological replicates per concentration.
- Fit sigmoidal curve (GraphPad Prism: log[agonist] vs. response, variable slope / 4-parameter model).
- Report EC₅₀ (splice-switching) or IC₅₀ (gapmer knockdown) with 95% confidence interval.
- Exclude concentrations causing overt cell toxicity or anomalous RT-PCR products.
- Statistics: one-way ANOVA + Tukey or Bonferroni post hoc correction. Significance threshold: p < 0.05.
Published EC₅₀ values for splice-switching ASOs in fibroblasts range from 13–56 nM (Hua et al., 2007). Typical dose-response experiments use 3-point (screening) to 8–10-point (full characterization) designs.
This protocol is compiled from published literature and is provided for informational purposes only. It does not constitute medical or laboratory guidance. All experimental work should be performed by qualified professionals following institutional protocols, biosafety regulations, and ethics approvals. Parameters must be optimized for each specific cell type, ASO chemistry, and target.
References
This protocol is compiled from the materials and methods of the following 10 studies.
- Kim J et al. Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. N Engl J Med. 2019;381:1644-1652.
- Hua Y et al. Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon. PLoS Biology. 2007;5(4):e73.
- Kim J et al. A framework for individualized splice-switching oligonucleotide therapy. Nature. 2023;619:828-836.
- Hiller M et al. A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping. PLoS ONE. 2018;13(10):e0204485.
- Echigoya Y et al. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Molecular Therapy. 2017;25:2561-2572.
- Gonzalez-Barriga A et al. Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes. Nucleic Acid Therapeutics. 2017;27:144-158.
- Wijaya YOS et al. High Concentration or Combined Treatment of Antisense Oligonucleotides for SMA Perturbed SMN2 Splicing in Patient Fibroblasts. Genes. 2022;13(4):685.
- Liang XH et al. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Molecular Therapy. 2017;25:2075-2092.
- Goyenvalle A et al. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic Acid Therapeutics. 2023;33:1-16.
- Aartsma-Rus A et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet. 2003;12:907-914.